A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A PHASE1 clinical study on Multiple Myeloma, this trial is actively recruiting participants. The trial is conducted by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company and has accumulated 13 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
May 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — May 2025 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Oct 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
For direct contact, visit the study record on ClinicalTrials.gov .